Expert Opinion on Drug Discovery
July 4, 2026
Christopher D. Verrico, Lynnette A. Averill, Cameron J Moore et al.
INTRODUCTION: Ibogaine is a naturally occurring indole alkaloid with suggested therapeutic potential across substance use disorders, trauma-related conditions, mood disorders, and suicidality. However, its clinical translation has been hindered by safety concerns, regulatory barriers, and uncertainty regarding its complex pharmacology. Recent interest has surged in developing ibogaine analogs...
Journal of Addiction Medicine
June 3, 2026
Ynhi T Thomas, Mubeen Iqbal, Chung J Mun et al.
Kratom ( Mitragyna speciosa ) is a psychoactive botanical with a long history of use in Southeast Asia and growing uptake in the United States for its analgesic, stimulant, and mood-altering properties. The evidence base remains limited, and retail products vary widely in composition and potency. This narrative review highlights what is known about kratom's pharmacology and suggests a practical...
The American journal of psychiatry
April 2014
Christopher D Verrico, Hong Gu, Melanie L Peterson et al.
Epidemiological findings suggest that, relative to adults, adolescents are more vulnerable to the adverse persistent effects of cannabis on working memory. However, the potential confounds inherent in human studies preclude direct determination of a cause-and-effect relationship between adolescent cannabis use and heightened susceptibility to persistent working memory impairments. Consequently,...
Journal of Psychopharmacology
January 21, 2008
Christopher D. Verrico, Laurie J. Lynch, Michele A. Fahey et al.
31 citations
Human MDMA (R,S-3,4-methylenedioxymethamphetamine) users display selective cognitive deficits after acute MDMA exposure, frequently attributed to serotonin deficits. We postulated that MDMA will compromize executive function in primates and that an inhibitor of the serotonin transporter (SERT) and the norepinephrine transporter (NET) but not the dopamine (DAT) transporter, will prevent...
Synapse (New York, N.Y.)
July 2003
Christopher D Verrico, J David Jentsch, Robert H Roth
Long-term abuse of delta-9-tetrahydrocannabinol (THC), the major psychoactive constituent of marijuana, produces behavioral and metabolic signs of frontal cortical dysfunction in humans; these effects persist even after short-term abstinence. Based on a preliminary finding that repeated administration of THC to rats reduces basal frontal cortical dopamine turnover (Jentsch et al. [1998]...
April 10, 1998
J. Jentsch, Christopher D. Verrico, D. Le et al.
Long-term abuse of marijuana by humans can induce profound behavioral deficits characterized by cognitive and memory impairments. In particular, deficits on tasks dependent on frontal lobe function have been reported in cannabis abusers. In the current study, we examined whether long-term exposure to delta9-tetrahydrocannabinol, the active ingredient in marijuana, altered the neurochemistry of...